Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Portfolio Pulse from
Xilio Therapeutics is set to present initial Phase 2 data for its tumor-activated anti-CTLA-4, Vilastobart (XTX101), in combination with Atezolizumab for metastatic microsatellite stable colorectal cancer at ASCO GI. Additionally, preliminary Phase 1 data for XTX301 shows improved tolerability over historical rhIL-12 data.
December 19, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xilio Therapeutics will present promising initial Phase 2 data for Vilastobart (XTX101) and preliminary Phase 1 data for XTX301, indicating potential advancements in cancer treatment.
The presentation of promising Phase 2 data for Vilastobart (XTX101) and improved tolerability for XTX301 suggests potential advancements in cancer treatment, which could positively impact Xilio Therapeutics' stock price. The news is highly relevant and important for investors as it indicates progress in their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100